Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Development of a rapid and sensitive multiple reaction monitoring proteomic approach for quantification of transporters in human liver tissue.

Wang L, Rubadue KJ, Alberts J, Bedwell DW, Ruterbories KJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:356-363. doi: 10.1016/j.jchromb.2017.07.051. Epub 2017 Aug 1.

PMID:
28800539
2.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.

Rougée LRA, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2017 Sep;45(9):1008-1018. doi: 10.1124/dmd.117.076331. Epub 2017 Jul 5.

PMID:
28679672
3.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates.

Rougée LR, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2016 Nov;44(11):1819-1827. Epub 2016 Sep 2.

PMID:
27590024
4.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.

Zhou X, Rougée LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, Ruterbories KJ.

Drug Metab Dispos. 2016 Aug;44(8):1184-92. doi: 10.1124/dmd.116.070623. Epub 2016 May 23.

PMID:
27217490
5.

In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.

Moulton RD, Ruterbories KJ, Bedwell DW, Mohutsky MA.

Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9.

PMID:
25755052
6.

High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.

Wickremsinhe ER, Lee LB, Schmalz CA, Torchia J, Ruterbories KJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:117-22. doi: 10.1016/j.jchromb.2013.06.008. Epub 2013 Jun 13.

PMID:
23831704
7.

Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles.

Wickremsinhe ER, Huang NH, Abdul BG, Knotts K, Ruterbories KJ, Manro JR.

Bioanalysis. 2013 Jan;5(2):159-70. doi: 10.4155/bio.12.309.

PMID:
23330559
8.

Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human.

Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H, Qian YW, Ruterbories KJ, Wrighton SA, Perkins EJ.

Drug Metab Dispos. 2011 Dec;39(12):2305-13. doi: 10.1124/dmd.111.041335. Epub 2011 Sep 14.

PMID:
21918037
9.

Dried blood spot sampling: coupling bioanalytical feasibility, blood-plasma partitioning and transferability to in vivo preclinical studies.

Wickremsinhe ER, Abdul BG, Huang NH, Richard JW, Hanes JL, Ruterbories KJ, Perkins EJ, Chaudhary AK.

Bioanalysis. 2011 Jul;3(14):1635-46. doi: 10.4155/bio.11.124.

PMID:
21756096
10.

Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.

Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK.

J Pharm Sci. 2011 Jun;100(6):2498-507. doi: 10.1002/jps.22452. Epub 2011 Jan 6.

PMID:
21213309
11.

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA.

Drug Metab Dispos. 2008 Jul;36(7):1227-32. doi: 10.1124/dmd.107.020248. Epub 2008 Mar 27.

PMID:
18372401
12.

Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.

Wickremsinhe ER, Tian Y, Ruterbories KJ, Verburg EM, Weerakkody GJ, Kurihara A, Farid NA.

Drug Metab Dispos. 2007 Jun;35(6):917-21. Epub 2007 Mar 12.

PMID:
17353347
13.

A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ.

J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):117-23.

PMID:
12481849
14.

Fused bicyclic Gly-Asp beta-turn mimics with potent affinity for GPIIb-IIIa. Exploration of the arginine isostere.

Fisher MJ, Giese U, Harms CS, Kinnick MD, Lindstrom TD, McCowan JR, Mest HJ, Morin JM Jr, Mullaney JT, Paal M, Rapp A, Rühter G, Ruterbories KJ, Sall DJ, Scarborough RM, Schotten T, Stenzel W, Towner RD, Um SL, Utterback BG, Wyss VL, Jakubowski JA.

Bioorg Med Chem Lett. 2000 Feb 21;10(4):385-9.

PMID:
10714506
15.

Fused bicyclic Gly-Asp beta-turn mimics with specific affinity for GPIIb-IIIa.

Fisher MJ, Arfstan AE, Giese U, Gunn BP, Harms CS, Khau V, Kinnick MD, Lindstrom TD, Martinelli MJ, Mest HJ, Mohr M, Morin JM Jr, Mullaney JT, Nunes A, Paal M, Rapp A, Rühter G, Ruterbories KJ, Sall DJ, Scarborough RM, Schotten T, Sommer B, Stenzel W, Towner RD, Um SL, et al.

J Med Chem. 1999 Nov 18;42(23):4875-89.

PMID:
10579850
16.

Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.

Su T, Naughton MA, Smyth MS, Rose JW, Arfsten AE, McCowan JR, Jakubowski JA, Wyss VL, Ruterbories KJ, Sall DJ, Scarborough RM.

J Med Chem. 1997 Dec 19;40(26):4308-18.

PMID:
9435900
17.

Statistical method for quantifying mobile phase selectivity in one- and two-dimensional overpressured layer chromatography.

Nurok D, Kleyle RM, McCain CL, Risley DS, Ruterbories KJ.

Anal Chem. 1997 Apr 1;69(7):1398-405. doi: 10.1021/ac960771e.

PMID:
21639345
18.

Benzylamine antioxidants: relationship between structure, peroxyl radical scavenging, lipid peroxidation inhibition, and cytoprotection.

Yu MJ, McCowan JR, Phebus LA, Towner RD, Ho PP, Keith PT, Luttman CA, Saunders RD, Ruterbories KJ, Lindstrom TD, et al.

J Med Chem. 1993 Apr 30;36(9):1262-71.

PMID:
8487263
19.

Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389.

Bendele AM, Ruterbories KJ, Spaethe SM, Benslay DN, Lindstrom TD, Lee SJ, Naismith RW.

J Pharmacol Exp Ther. 1992 Mar;260(3):1194-8.

PMID:
1545387
20.

Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis.

Bendele AM, Benslay DN, Hom JT, Spaethe SM, Ruterbories KJ, Lindstrom TD, Lee SJ, Naismith RW.

J Pharmacol Exp Ther. 1992 Jan;260(1):300-5.

PMID:
1309875
21.
22.

Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.

Lindstrom TD, Althaus WA, Ruterbories KJ, Kau D.

J Pharmacol Exp Ther. 1990 Mar;252(3):1117-24.

PMID:
2319463

Supplemental Content

Loading ...
Support Center